Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Kristina L. Bailey; Andre C. Kalil

doi:10.1007/s11908-015-0494-5

Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Kristina L. Bailey, Andre C. Kalil

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

Original language	English (US)
Article number	39
Journal	Current Infectious Disease Reports
Volume	17
Issue number	8
DOIs	https://doi.org/10.1007/s11908-015-0494-5
State	Published - Aug 23 2015

Keywords

Antibiotics
Outcomes
Ventilator-associated pneumonia

ASJC Scopus subject areas

Infectious Diseases

Access to Document

10.1007/s11908-015-0494-5

Cite this

@article{f0d3902661564798a2fbc9a0fea2a957,

title = "Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?",

abstract = "Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.",

keywords = "Antibiotics, Outcomes, Ventilator-associated pneumonia",

author = "Bailey, {Kristina L.} and Kalil, {Andre C.}",

note = "Publisher Copyright: {\textcopyright} 2015, Springer Science+Business Media New York.",

year = "2015",

month = aug,

day = "23",

doi = "10.1007/s11908-015-0494-5",

language = "English (US)",

volume = "17",

journal = "Current Infectious Disease Reports",

issn = "1523-3847",

publisher = "Current Science, Inc.",

number = "8",

}

TY - JOUR

T1 - Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens

T2 - Optimal Treatment?

AU - Bailey, Kristina L.

AU - Kalil, Andre C.

PY - 2015/8/23

Y1 - 2015/8/23

N2 - Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

AB - Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

KW - Antibiotics

KW - Outcomes

KW - Ventilator-associated pneumonia

UR - http://www.scopus.com/inward/record.url?scp=84935024029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935024029&partnerID=8YFLogxK

U2 - 10.1007/s11908-015-0494-5

DO - 10.1007/s11908-015-0494-5

M3 - Review article

C2 - 26092246

AN - SCOPUS:84935024029

SN - 1523-3847

VL - 17

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

IS - 8

M1 - 39

ER -

Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this